CFO
DYN icon

CVA Family Office’s Dyne Therapeutics DYN Stock Holding History

CVA Family Office’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12
Closed -$431 – 1304
2024
Q3 		$431 Buy
+12
New +$478 ﹤0.01% 1241

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CVA Family Office's DYN Position: Q4 2024 in Review

CVA Family Office sold out of Dyne Therapeutics (DYN) in Q4 2024, closing a stake of 12 shares — an estimated $431 sold.

CVA Family Office first reported a position in DYN in Q3 2024 and held it in 1 quarter. The position peaked at $431 in Q3 2024. 200 funds tracked by Wall St. Rank hold DYN as of Q4 2024.

  • CVA Family Office reported no remaining Dyne Therapeutics position as of Q4 2024 after selling out during the quarter.
  • CVA Family Office sold 12 Dyne Therapeutics shares in Q4 2024, an estimated $431.
  • CVA Family Office first reported a position in Dyne Therapeutics in Q3 2024 and held it in 1 quarter.
  • CVA Family Office's Dyne Therapeutics position peaked at $431 in Q3 2024.
  • 200 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2024.

Based on CVA Family Office's 13F filing for Q4 2024, filed 7 Jan 2025.